title: Pediatric renal transplantation under FK-506 immunosuppression.
abstract: Renal transplantation (11 cadaveric and 1 living-related donor) was performed in 12 pediatric recipients (mean age 10.8 years) under FK-506 immunosuppression in combination with prednisone therapy. At a mean followup of 6.1 months, patient and graft survival rates were 100% and 92%, respectively. The only graft loss was due to the recurrent hemolytic uremic syndrome 4 days after transplantation. In the functioning grafts the mean serum creatinine is 1.59 +/- 1.27 mg./dl. and the mean blood urea nitrogen is 36.3 +/- 24.6 mg./dl. Three patients take no prednisone, 5 are receiving 0.15 to 0.25 mg./kg. per day and 3 are taking 0.35 to 0.5 mg./kg. per day. There was a total of 8 rejection episodes in 5 patients. All rejection episodes were successfully reversed. Complications of transplantation included an episode of seizures in 1 patient, cytomegalovirus infection in 1 and steroid-induced diabetes mellitus in 1. Since pediatric transplant recipients are a group in whom the reduction or elimination of steroids is highly desirable, FK-506 immunosuppression may be particularly suited for use in this population.
authors.affiliation: Department of Surgery, University of Pittsburgh School of Medicine, Pennsylvania.
authors.forename: F X
authors.initials: FX
authors.lastname: Schneck
authors.forename: M L
authors.initials: ML
authors.lastname: Jordan
authors.forename: C W
authors.initials: CW
authors.lastname: Jensen
authors.forename: R
authors.initials: R
authors.lastname: Shapiro
authors.forename: A
authors.initials: A
authors.lastname: Tzakis
authors.forename: V P
authors.initials: VP
authors.lastname: Scantlebury
authors.forename: D
authors.initials: D
authors.lastname: Ellis
authors.forename: N
authors.initials: N
authors.lastname: Gilboa
authors.forename: R L
authors.initials: RL
authors.lastname: Simmons
authors.forename: T R
authors.initials: TR
authors.lastname: Hakala
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation / Q000009:adverse effects / Q000401:mortality; D008297:Male; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use*
chemical_list: D016559:Tacrolimus